Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score-Reference-Cited by-同舟云学术

Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score

Published:2019-06-24 Issue:2 Volume:177 Page:437-446
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Michel Laura L.^ORCID,Sommer Laura,González Silos Rosa,Lorenzo Bermejo Justo,von Au Alexandra,Seitz Julia,Hennigs André,Smetanay Katharina,Golatta Michael,Heil Jörg,Schütz Florian,Sohn Christof,Schneeweiss Andreas,Marmé Frederik

Funder

Medizinischen Fakultät Heidelberg, Universität Heidelberg

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05314-9.pdf

Reference29 articles.

1. Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223

2. Hortobagyi GN, Blumenschein GR, Spanos W et al (1983) Multimodal treatment of locoregionally advanced breast cancer. Cancer 51:763–768

3. Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

4. Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284. https://doi.org/10.1093/annonc/mdt182

5. von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309. https://doi.org/10.1056/NEJMoa1111065

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strahlentherapeutische Konzepte nach Neoadjuvanz;Die Gynäkologie;2023-04-27

2. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer;Clinical Breast Cancer;2022-01

3. Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy;Breast Cancer Research and Treatment;2021-01-08

4. Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy;Breast Cancer Research and Treatment;2020-11-09

5. Loco-regional therapy for isolated locoregional lymph node recurrence of breast cancer: focusing on surgical treatment with combined therapy;Translational Cancer Research;2020-08